Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANAVEX3-71 in schizophrenia
NCT06245213Phase 2Active, not recruiting
- Sponsor
- Anavex Life Sciences Corp.
- Start
- Mar 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of anavex 3-71 in schizophrenia (5 arms), sponsored by Anavex Life Sciences Corp. Primary endpoints: Maximum Observed Plasma Concentration at Day 9, Time to Maximum Plasma Concentration at Day 9 and 13 more. Started Mar 2024; status: active, not recruiting.
02
Drugs
anavex 3-71
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06245213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06245213.